Drugs / INCB161734
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07854249 | Oct 2026 → Mar 2027 expected | impaired renal function disease | Incyte Corporation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07853040 | Oct 2026 → Mar 2027 expected | liver disorder | Incyte Corporation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07814404 | Sep → Oct 2026 expected | — | Incyte Corporation | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07018635 | Jul → Sep 2025 | — | Incyte Corporation | Completed | No outcome recorded |
| Phase 1 | NCT06179160 | Jan 2024 → Jan 2027 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07522073 | Apr 2026 → Sep 2028 expected | cancer | Incyte Corporation | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-19 | Incyte Corporation | Results Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma incyte.com ↗
Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patients |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | INCB161734 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07018635 ↗ |
| Route | Oral | “Oral; Tablet” NCT07018635 ↗ |